“The identification of early cancer risk is no longer a formidable challenge, as the Marker Exploration Corporation (Marker X) AI's early multi-cancer screening demonstrates an accuracy rate exceeding 90%.”

Cancer ranks as the second leading cause of global mortality, with an anticipated annual increase to 13 million deaths in the next 20 years. By 2030, cancer-related deaths are expected to rise to 1.5 times the current figure. In contrast to the traditional tumor indices, which exhibit only around 50% specificity and sensitivity in detecting early-stage cancers (Stages 0-1), Marker X has pioneered a breakthrough approach. Integrating high-resolution mass spectrometry, AI deep learning, and the exclusive "multi-indicator algorithm," the company has successfully developed an early cancer screening index with an accuracy exceeding 95%. Several prevalent cancers among the Taiwanese population, including lung cancer, colorectal cancer, breast cancer, and esophageal cancer, are now detectable through this screening, aiding in assessing cancer risks and safeguarding individual health.

“Marker X AI Early Multi-Cancer Screening: Efficient, Convenient, Low Invasiveness”

Diverging from conventional examination methods, Marker X AI's early multi-cancer screening offers distinct advantages. Requiring only a small blood sample, the procedure involves no radiation risk and eliminates the need for intricate endoscopic examinations. The sensitivity of the screening encompasses early-stage in situ cancers and Stage I cancers, making it particularly suitable for high-risk populations, with the goal of achieving early detection. With a mere 3ml blood extraction, results are obtainable within 10 working days, eliminating the inconvenience of hospital visits across different departments and significantly reducing result waiting times.

“Three Major Trends in the Taiwanese Cancer Population: Acceleration, Youthfulness, Chronicization”

For 41 consecutive years, cancer has been the leading cause of death in Taiwan, with one person diagnosed with cancer every 4 minutes and 20 seconds. Over 83% of cancer patients are concentrated in the 50-and-above age group, with a median age of 64. However, individuals under 45 years old without a family history are also susceptible to cancer, as approximately 70% of cancer patients do not have a familial predisposition. Over the past 30 years, the incidence rate among individuals under 40 has increased tenfold, from approximately 25 individuals in 1990 to over 6,000 in 2020. Among the over 90,000 individuals diagnosed with cancer in Taiwan in 2023, over 10% are below the age of 45, emphasizing the impact on life plans such as work, marriage, and parenting.

Early Detection Equals High Cure Rates: The Role of Marker X AI Early Multi-Cancer Screening

Contrary to considering cancer a terminal diagnosis, early detection of in situ or Stage I cancer results in cure rates ranging from 95% to 100%. Following treatment completion, regular follow-up visits enable patients to lead normal lives, sparing them from the physical, emotional, and significant economic burdens associated with advanced cancer.

Marker X AI Early Multi-Cancer Screening provides individuals concerned about cancer risk with a valuable opportunity to control their risks, assisting users in early detection and treatment. It is recommended that individuals aged 30 and above, especially those with a family history of cancer and high-risk lifestyles, undergo regular screenings to proactively safeguard their health.

“Unveiling the Mystery of Early Cancer Risk with Cancer Proteomics”

Marker X employs proprietary, efficient technology to unlock the secrets of "cancer proteomes" in the blood. Proteins serve as the core of life activities, and differences in translated and modified signals in plasma proteins become clues for effectively detecting cancer at an early stage. Through clinical blood samples, coupled with AI machine learning and big data algorithms, we have developed a cancer proteome risk indicator model that differentiates cancer patients from healthy individuals. This model assists individuals in evaluating their current cancer risk based on blood samples, effectively indicating the risk of cancer at the time of blood extraction.

“National Recognition: Marker Exploration Corporation(Marker X) Adds Color to Taiwan's Biotechnology Revolution”

Marker Exploration Corporation recently received recognition at the 20th National Innovation Awards of Taiwan in 2023, specifically in the category of startup enterprises. This acknowledgment not only signifies the approval of the evaluation committee for Marker X AI's early multi-cancer screening technology but also injects a dose of confidence into Taiwan's innovative prowess in the biotechnology and broader health sectors. This honor demonstrates the power of technology in creating visionary solutions for people and lays a solid foundation for the future development of preventive medicine and precision testing industries.